Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid

Clinical Cancer Research

Volumn 10, Issue 18 II, 2004, Pages

  Lipton, Allan ^a,f   Colombo Berra, Alejandro ^b   Bukowski, Ronald M ^c   Rosen, Lee ^d   Zheng, Ming ^e   Urbanowitz, Gladys ^e   Figlin, Robert ^g   Yang, James ^g   Gordon, Michael ^g   Stadler, Walter ^g   Eisen, Tim ^g   George, Daniel ^g  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b Hospital Provincial de Rosario   (Argentina)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Cancer Institute Medical Group   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f PENNSYLVANIA STATE UNIVERSITY   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; VITAMIN D; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ACUTE PHASE RESPONSE; BONE DISEASE; BONE METASTASIS; BREAST TUMOR; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG INFUSION; FATIGUE; FEVER; FRACTURE; HEMATURIA; HIGH RISK POPULATION; HUMAN; HYPERURICEMIA; INCIDENCE; KIDNEY CARCINOMA; KIDNEY FAILURE; LEG EDEMA; META ANALYSIS; MICTURITION DISORDER; MORBIDITY; NAUSEA; NEPHROTOXICITY; OBSTRUCTIVE UROPATHY; OLIGURIA; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RIGOR; RISK REDUCTION; SIDE EFFECT; SPINAL CORD COMPRESSION; SYSTEMATIC REVIEW; TIME;

BONE DISEASES; BONE NEOPLASMS; BONE RESORPTION; CARCINOMA, RENAL CELL; DIPHOSPHONATES; HUMANS; IMIDAZOLES; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; OSTEOLYSIS;

EID: 4644340347     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-040030     Document Type: Conference Paper

References (26)

1. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2000. National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975 2000. Accessed July 6, 2004.
2. Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001;19:379-82.
3. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76.
4. Weinfurt KP, Li Y, Castel LD, Timbie JW, Glendenning A, Schulman KA. The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer [abstract]. Ann Oncol 2002;13(suppl 5):180. Abstract 662P.
5. Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002;25(suppl 1):S10-8.
6. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98:962-9.
7. Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 2003;61:314-9.
8. Mitchell MS. Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and interleukin-2. Semin Oncol 1992;19(suppl 4):80-7.
9. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69:1-18.
10. Goltzman D, Karaplis AC, Kremer R, Rabbani SA. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 2000;88(suppl):2903-8.
11. Mundy GR. Metastatic bone disease. In: GR. Mundy and A Mundy, editors. Bone Remodeling and Its Disorders, 2nd edition. London: Martin Dunitz, Ltd., 1998. pp. 123-46.
12. Benford HL, Frith JC, Auriola S, Mönkkönen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131-40.
13. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100.
14. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-7.
15. Lipton A, Seaman J, Zheng M. Efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. Presented at: What Is New in Bisphosphonates? Seventh Workshop on Bisphosphonates-From the Laboratory to the Patient; March 24-26, 2004; Davos, Switzerland. Poster 28.
16. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982;10:1100-20.
17. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
18. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999;17:846-54.
19. Lipton A. Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 2003;8:469-88.
20. Tchekmedyian S, Rosen LS, Gordon D, et al. Long-term efficacy and safety of zoledronic acid in reducing skeletal complications in patients with bone metastases from solid tumors [abstract]. Proc Am Soc Clin Oncol 2003;22:630. Abstract 2532.
21. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90.
22. Maxwell C, Swift R, Goode M, Doane L, Rogers M. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. Clin J Oncol Nurs 2003;7:403-8.
23. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. (Cochrane Review). In: The Cochrane Library, Issue 2. Chichester, UK: John Wiley & Sons, Ltd, 2004.
24. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057. Published erratum in: J Clin Oncol 2004;2003;22:1351.
25. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057. Published erratum in: J Clin Oncol 2004;2003;22:1351.
26. Clezardin P. The antitumor potential of bisphosphonates. Semin Oncol 2002;29(suppl 21):33-42.